Eli Lilly Announces Leadership Changes for Growth
Eli Lilly and Company (NYSE: LLY) recently announced significant transitions in its executive leadership team. This strategic move is designed to bolster the company’s potential for sustained, long-term growth and ensure that its innovative medicines reach more individuals around the world.
Focus on U.S. and Global Markets
Lilly has witnessed remarkable growth in recent years, especially within the U.S. and its cardiometabolic health sectors. The company expects this momentum to continue, along with advancements in its product pipeline. To harness this potential, Lilly is sharpening its focus on the U.S. market and its global therapeutic areas.
New Roles for Key Executives
Ilya Yuffa, previously serving as the executive vice president and president of Lilly International, will step into a new role as executive vice president and president of Lilly USA and Global Customer Capabilities. In his new position, Yuffa will oversee the U.S. business, which includes sales, marketing, and the commercial strategy for all marketed products. He will also take responsibility for the upcoming product launches in the U.S. market.
Leadership Transition for International Market
Patrik Jonsson, who held the role of executive vice president and president of Lilly Cardiometabolic Health and president of Lilly USA, will now assume the position of executive vice president and president of Lilly International, responsible for all markets outside the U.S. Jonsson’s successful leadership in driving the cardiometabolic and U.S. businesses will aid in bolstering Lilly’s international growth.
Promotion and Experience of Kenneth Custer
Kenneth Custer, Ph.D., current general manager of Lilly Canada, is poised to be promoted to executive vice president and president of Lilly Cardiometabolic Health. He will also join Lilly’s executive committee. Custer, a dedicated member of the Lilly team for 16 years, began his career in sales and marketing and later transitioned to Lilly Research Laboratories (LRL), where he led crucial developments in immunology and diabetes treatment, including notable programs like tirzepatide.
Commitment to Long-Term Growth
“Thanks to Patrik's leadership, Lilly’s cardiometabolic health and U.S. businesses have achieved tremendous growth in recent years,” remarked David A. Ricks, Lilly's chair and CEO. “With these changes, we are creating the focused leadership necessary to propel us to the next level. I am confident that Patrik, Ilya, and Ken will continue to drive our long-term strategy to discover, develop, and deliver medicines that genuinely improve lives.”
About Eli Lilly and Company
Eli Lilly is renowned for turning scientific knowledge into effective medicines, aiming to enhance the quality of life for patients globally. With a legacy of 150 years of innovation, Lilly helps millions access transformative medicines. Guided by advancements in biotechnology and genetic medicine, the company is passionately tackling critical health challenges, including:
• Redefining diabetes management
• Addressing obesity and its long-term impact
• Combatting Alzheimer’s disease
• Offering solutions to complex immune disorders
• Transforming hard-to-treat cancers into more manageable conditions
As part of its mission, Lilly is committed to diversity in clinical trials and strives to ensure its medicines are economically accessible. For further information, visit Lilly.com or follow on various social media platforms to stay updated with the latest news and innovations.
Frequently Asked Questions
What recent leadership transitions has Eli Lilly announced?
Eli Lilly has announced significant leadership changes to enhance their focus on U.S. and global business operations, including new roles for Ilya Yuffa, Patrik Jonsson, and Kenneth Custer.
What will Ilya Yuffa's new role entail?
Ilya Yuffa will oversee Lilly's U.S. business, including sales and marketing, along with leading global customer capabilities.
How does Patrik Jonsson's new position support international growth?
Patrik Jonsson’s extensive experience in successful product launches and market leadership will enable him to guide Lilly's growth efforts internationally.
What is Kenneth Custer's background at Lilly?
Kenneth Custer has been with Lilly for 16 years, with experience in sales, marketing, and leading key development programs in diabetes and immunology.
What is Eli Lilly's mission?
Eli Lilly's mission is to make life better through science, developing medicines that address significant health challenges and ensuring they are accessible to those in need.
